AMENDMENTS TO THE CLAIMS

The listing of the claims replaces all prior versions and listings of the claims for this application. Within this listing of the claims, claims 30-33, 35, 36, and 40-44 are newly canceled.

1. **(previously presented)** A method for treating a patient suffering from or predisposed to developing interstitial lung disease (ILD), comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing.

2. **(original)** The method of claim 1, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

3. **(original)** The method of claim 2, wherein the active agent is *cis*-resveratrol.

4. **(original)** The method of claim 2, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.

5. **(original)** The method of claim 4, wherein the active agent is *cis*-resveratrol glucoside.

6. **(original)** The method of claim 1, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

7. **(original)** The method of claim 6, wherein the active agent is *trans*-resveratrol.

8. **(original)** The method of claim 6, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.

9. **(original)** The method of claim 8, wherein the active agent is *trans*-resveratrol glucoside.

10. **(original)** The method of claim 1, wherein the active agent comprises a mixture of *cis*-resveratrol and *trans*-resveratrol.

11. **(original)** The method of claim 1, wherein the active agent is delivered orally.

12. **(original)** The method of claim 1, wherein the active agent is delivered by pulmonary administration.

13. **(original)** The method of claim 1, wherein the active agent is delivered parenterally.

14. **(original)** The method of claim 13, wherein the active agent is delivered to the alveoli.

15-23. **(canceled)**

24. **(original)** The method of claim 1, further comprising the co-administration of an additional active agent.

25. **(original)** The method of claim 24, wherein the formulation further includes an additional active agent.

26. **(original)** The method of claim 25, wherein the additional active agent is selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

27. **(previously presented)** The method of claim 26, wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting β_2 adrenergic agonists, and combinations thereof.

28. **(original)** The method of claim 27, wherein the additional active agent is selected from the group consisting of theophylline, salmetrol xinafoate, and a combination thereof.

29-37. **(canceled)**

38. **(previously presented)** The method of claim 1, wherein the ILD is fibrosing alveolitis, sarcoidiosis, or fibrotic lung disease.

39-44. **(canceled)**